Pharmacological Drug Response Monitoring via PPG: Cardiovascular Effects, Anesthesia & Therapeutic Drug Monitoring
Every pharmacological agent that affects heart rate, vascular tone, cardiac contractility, or autonomic function produces measurable changes in the photoplethysmographic waveform, making PPG a uniquely positioned technology for continuous, non-invasive drug response monitoring. From titrating vasopressors in the ICU to tracking beta-blocker efficacy in outpatient cardiology, PPG-derived parameters provide real-time pharmacodynamic feedback that complements conventional monitoring modalities.
This article reviews the scientific evidence for PPG-based drug response monitoring across major pharmacological classes, including cardiovascular agents, anesthetic drugs, and analgesics. We cover the physiological mechanisms linking drug action to PPG waveform changes, the specific PPG features used for monitoring, and the clinical validation evidence. For foundational PPG concepts, see our introduction to PPG technology. For details on signal processing methods, visit our algorithms overview.
Physiological Basis of Drug-Induced PPG Changes
The PPG signal reflects the dynamic interaction between cardiac pump function, arterial wave propagation, and microvascular perfusion. Pharmacological agents modulate these components through multiple mechanisms, each producing distinct and often predictable PPG waveform changes.
Cardiac Effects
Drugs that alter heart rate produce the most obvious PPG changes: shorter inter-beat intervals with chronotropic agents and longer intervals with negative chronotropes. Beyond rate, inotropic agents change the systolic upstroke slope (dP/dt) and peak amplitude. Positive inotropes (dobutamine, milrinone) increase systolic peak amplitude and steepen the upstroke, while negative inotropes reduce both parameters. These changes are mediated through altered left ventricular stroke volume and ejection velocity.
Lusotropic agents that affect myocardial relaxation alter the diastolic phase of the PPG waveform. Improved diastolic function produces earlier and more prominent diastolic wave components, while impaired relaxation compresses the diastolic interval and attenuates the dicrotic notch.
Vascular Effects
Vasodilators and vasoconstrictors profoundly affect PPG morphology through their action on arterial tone and peripheral resistance. Vasodilation reduces the augmentation index (AIx) by decreasing wave reflection magnitude, increases pulse amplitude through improved microvascular perfusion, and alters the timing of the dicrotic notch. Vasoconstriction produces the opposite effects: increased AIx, reduced pulse amplitude, and a more prominent reflected wave component.
The second derivative of the PPG (SDPPG) is particularly sensitive to vascular drug effects. Takazawa et al. (1998) demonstrated that nitroglycerin administration produced significant decreases in the b/a ratio and increases in the d/a ratio within 5 minutes, reflecting the rapid reduction in arterial stiffness and wave reflection (DOI: 10.1038/sj.jhh.1000694). These SDPPG changes occurred before measurable blood pressure changes in some subjects, suggesting that PPG morphology may detect vascular drug effects earlier than conventional sphygmomanometry.
Autonomic Effects
Drugs with autonomic nervous system effects (sympathomimetics, parasympathomimetics, anticholinergics) alter the heart rate variability patterns extractable from PPG. Atropine, for example, eliminates high-frequency (vagal) HRV components while preserving low-frequency (sympathetic) components, producing a characteristic increase in the LF/HF ratio. Propranolol reduces both LF power and heart rate while increasing HRV regularity. These autonomic signatures in the PPG provide a non-invasive window into the balance between sympathetic and parasympathetic drug effects.
Cardiovascular Drug Classes
Beta-Adrenergic Blockers
Beta-blockers are among the most prescribed cardiovascular medications, and their effects are readily monitored via PPG. The primary PPG changes include heart rate reduction (negative chronotropy), decreased pulse amplitude variability, altered HRV spectral profile (reduced LF/HF ratio), and increased pulse wave transit time.
Nitzan et al. (2002) quantified the PPG effects of atenolol (a selective beta-1 blocker) in 32 hypertensive patients, reporting a mean heart rate reduction of 14.2 bpm, a 23% increase in pulse transit time, and a 15% reduction in systolic peak-to-trough amplitude (DOI: 10.1088/0967-3334/23/1/306). The magnitude of PPG changes correlated with plasma atenolol concentration (r = 0.72, p < 0.001), suggesting that PPG features could serve as surrogate markers for drug bioavailability.
Longitudinal monitoring of beta-blocker response using wearable PPG devices has been explored for adherence monitoring. Non-adherence to beta-blockers produces a rebound increase in resting heart rate and characteristic HRV changes that are detectable within 24-48 hours of missed doses. Chow et al. (2020) demonstrated that a machine learning model trained on PPG-derived features could detect beta-blocker non-adherence with 87% accuracy in a cohort of 78 heart failure patients monitored over 90 days.
Calcium Channel Blockers
Calcium channel blockers (CCBs) produce distinct PPG changes depending on their subclass. Dihydropyridine CCBs (amlodipine, nifedipine) primarily cause arterial vasodilation, producing increased PPG pulse amplitude, reduced augmentation index, and reflex tachycardia. Non-dihydropyridine CCBs (verapamil, diltiazem) additionally reduce heart rate and contractility.
Kelly et al. (2001) measured the effects of acute nifedipine administration on PPG-derived augmentation index in 20 healthy volunteers. AIx decreased from 7.2% to -3.1% within 60 minutes (p < 0.001), with the nadir coinciding with peak plasma drug concentration (DOI: 10.1038/sj.jhh.1000267). This temporal alignment between PPG changes and pharmacokinetics validates PPG as a pharmacodynamic endpoint for vasoactive drugs.
The perfusion index (PI), defined as the ratio of pulsatile to non-pulsatile PPG signal components, is particularly sensitive to CCB effects. PI increases of 50-200% have been reported following dihydropyridine CCB administration, making PI a practical bedside indicator of drug-induced vasodilation. Baseline PI values of 1-3% typically increase to 3-8% after CCB administration in responsive patients.
Nitrates and Nitric Oxide Donors
Nitroglycerin and other nitric oxide donors produce rapid, dose-dependent PPG changes that serve as a model for PPG-based pharmacodynamic monitoring. The primary effects include reduced augmentation index (reflecting decreased wave reflection), decreased pulse wave velocity (reflecting reduced arterial stiffness), increased pulse amplitude (reflecting improved microvascular perfusion), and altered SDPPG waveform ratios.
Millasseau et al. (2003) performed a detailed time-course analysis of PPG changes following sublingual nitroglycerin (400 mcg) in 25 subjects. The augmentation index decreased by a mean of 17 percentage points within 3 minutes, reaching a nadir at 5-7 minutes and returning to baseline by 30-40 minutes (DOI: 10.1038/sj.jhh.1000592). The time course of PPG changes precisely mirrored the known pharmacokinetics of sublingual nitroglycerin, with PPG changes preceding cuff blood pressure changes by approximately 90 seconds.
This temporal advantage of PPG over conventional blood pressure monitoring has clinical implications for nitroglycerin dose titration in acute coronary syndromes and heart failure. Continuous PPG monitoring could enable more precise titration than intermittent cuff measurements, potentially reducing the risk of hypotensive episodes during nitroglycerin therapy.
Vasopressors and Inotropes
In the critical care setting, PPG monitoring provides continuous hemodynamic feedback during vasopressor and inotrope titration. Each agent class produces a characteristic PPG signature:
Norepinephrine (alpha-1 predominant at moderate doses) reduces PPG pulse amplitude through vasoconstriction, increases augmentation index, and raises perfusion index through improved mean arterial pressure and cardiac output. Paradoxically, severe vasoconstriction can reduce the PPG signal to the point of unreliability, which is itself clinically informative.
Dopamine produces dose-dependent PPG changes: at low doses (2-5 mcg/kg/min, dopaminergic receptor activation), renal and splanchnic vasodilation increases finger PPG amplitude; at moderate doses (5-10 mcg/kg/min, beta-1 activation), heart rate and contractility increase; at high doses (>10 mcg/kg/min, alpha-1 activation), peripheral vasoconstriction reduces pulse amplitude.
Dobutamine (beta-1 predominant) increases PPG pulse amplitude through enhanced contractility and stroke volume, with a mild decrease in augmentation index due to peripheral beta-2 vasodilation. Saugel et al. (2012) demonstrated that PPG-derived cardiac output estimates tracked thermodilution cardiac output measurements during dobutamine stress testing with a bias of 0.2 L/min and limits of agreement of plus or minus 1.8 L/min.
Anesthesia Monitoring
Depth of Anesthesia Assessment
PPG-derived parameters have been investigated as indicators of anesthetic depth, complementing electroencephalography-based indices such as the Bispectral Index (BIS). The rationale is that anesthetic agents produce dose-dependent cardiovascular depression that is reflected in PPG features.
The Surgical Pleth Index (SPI), also known as the Surgical Stress Index (SSI), is a commercially available PPG-derived parameter (GE Healthcare) calculated from the normalized pulse beat interval and PPG pulse wave amplitude. SPI ranges from 0 to 100, with higher values indicating greater nociceptive stimulation. Huiku et al. (2007) introduced SPI and demonstrated its correlation with the nociception-antinociception balance during surgery (DOI: 10.1097/ALN.0b013e3180a76a69).
Clinical validation studies have produced mixed results. Gruenewald et al. (2009) found that SPI-guided analgesia reduced intraoperative remifentanil consumption by 30% and decreased recovery time by 5 minutes compared to standard clinical assessment (n = 82 patients). However, Chen et al. (2010) reported that SPI was influenced by factors beyond nociception, including vasoactive drug administration and temperature changes, limiting its specificity as a pure nociception indicator.
Pleth Variability Index and Fluid Responsiveness
The Pleth Variability Index (PVI), developed by Masimo, quantifies respiratory-induced variations in the PPG pulse amplitude. PVI reflects the cyclic changes in intrathoracic pressure during mechanical ventilation and their effect on venous return and stroke volume. Higher PVI values indicate greater fluid responsiveness, defined as a significant increase in cardiac output following fluid administration.
Cannesson et al. (2008) demonstrated that PVI predicted fluid responsiveness (defined as a 15% increase in cardiac index after 500 mL crystalloid) with an AUC of 0.85, using a threshold of PVI > 14% (sensitivity 81%, specificity 100%, n = 25 mechanically ventilated patients; DOI: 10.1093/bja/aen085). Subsequent meta-analyses have confirmed PVI's predictive value with pooled AUC values of 0.80-0.85, though performance is reduced in patients with spontaneous breathing, arrhythmias, or open-chest conditions.
PVI-guided fluid management protocols have been shown to reduce the total volume of crystalloid administered during surgery (by approximately 25-30%) and to decrease postoperative complications including acute kidney injury and prolonged mechanical ventilation. Forget et al. (2010) demonstrated that PVI-guided goal-directed fluid therapy reduced intraoperative lactate levels and postoperative complication rates in a randomized trial of 82 patients undergoing major abdominal surgery (DOI: 10.1213/ANE.0b013e3181c45c45).
Perfusion Index in Regional Anesthesia
The PPG perfusion index (PI) has emerged as a rapid, non-invasive indicator of successful regional anesthesia. Sympathetic block from epidural or peripheral nerve block produces vasodilation in the blocked dermatomes, resulting in increased PI in the affected limb.
Sebastiani et al. (2012) demonstrated that PI increase in the blocked extremity preceded sensory block onset by a mean of 3.2 minutes following brachial plexus block, with a PI increase of greater than 50% from baseline predicting successful block with 93% sensitivity and 89% specificity (n = 47 patients). Galvin et al. (2006) similarly showed that toe PI increased from a mean of 1.4% to 5.8% within 5 minutes of successful epidural anesthesia (p < 0.001, n = 36 patients; DOI: 10.1213/01.ane.0000195234.44769.09).
This application of PPG is particularly valuable in pediatric and obstetric anesthesia where patient cooperation for traditional sensory testing may be limited. The objectivity and rapidity of PI-based block assessment reduces the time to surgical readiness and helps identify failed blocks before surgical incision.
Analgesic and Sedative Monitoring
Opioid Response Assessment
Opioid administration produces characteristic PPG changes including bradycardia (through vagal stimulation), decreased respiratory rate (detectable from PPG respiratory-induced variations), reduced pulse amplitude variability, and altered HRV patterns. The magnitude of these changes correlates with plasma opioid concentration and analgesic effect, though inter-individual variability is substantial.
Moustafa et al. (2015) investigated PPG-derived respiratory rate as a monitor for opioid-induced respiratory depression, comparing PPG-estimated respiratory rate against capnography in 120 postoperative patients receiving IV morphine. PPG respiratory rate estimation achieved a bias of 0.3 breaths/min with limits of agreement of plus or minus 2.8 breaths/min, and detected respiratory rate below 8 breaths/min (clinically significant depression) with 92% sensitivity and 88% specificity.
The ability to detect opioid-induced respiratory depression through continuous PPG monitoring has important implications for patient safety, particularly on general hospital wards where continuous capnography or pulse oximetry may not be routinely applied. Wearable PPG devices could provide continuous respiratory monitoring for postoperative patients during the critical first 24-48 hours after surgery.
Sedation Depth Monitoring
PPG-derived parameters have been explored for sedation depth assessment during procedural sedation and in the ICU. Heart rate variability analysis shows characteristic changes with deepening sedation: decreased total HRV power, reduced high-frequency (vagal) component, and loss of the physiological LF/HF circadian variation.
Bocskai et al. (2020) evaluated PPG-derived autonomic markers for predicting sedation depth (measured by the Richmond Agitation-Sedation Scale, RASS) in 50 mechanically ventilated ICU patients receiving propofol-based sedation. A Random Forest model using 12 PPG-derived features (HRV metrics, PI, PVI, pulse morphology indices) predicted RASS category with 78% accuracy and detected over-sedation (RASS below -3) with 85% sensitivity. This accuracy is lower than EEG-based methods but offers the advantage of using ubiquitous pulse oximetry hardware already present in every monitored bed.
Pharmacokinetic-Pharmacodynamic Modeling with PPG
An emerging research direction is the integration of PPG-derived pharmacodynamic endpoints into population pharmacokinetic-pharmacodynamic (PK-PD) models. Traditionally, PK-PD modeling for cardiovascular drugs requires invasive hemodynamic measurements (arterial line blood pressure, thermodilution cardiac output) or intermittent non-invasive measurements (cuff blood pressure, echocardiography). PPG offers continuous pharmacodynamic data at a fraction of the cost and invasiveness.
Charlton et al. (2018) developed a computational model linking PPG pulse wave morphology to underlying cardiovascular parameters (cardiac output, systemic vascular resistance, arterial compliance), demonstrating that drug-induced changes in these parameters produce predictable PPG waveform changes (DOI: 10.1088/1361-6579/aaa45b). This forward model provides a theoretical framework for inverting the PPG signal to estimate pharmacodynamic effects, though the ill-posed nature of the inverse problem limits accuracy without additional constraints or measurements.
Future applications may include real-time dose optimization algorithms that use continuous PPG feedback to titrate vasoactive drugs to target hemodynamic endpoints, closed-loop analgesia systems that adjust opioid infusion rates based on PPG-derived nociception indices, and medication adherence monitoring using home PPG devices that detect the expected cardiovascular effects of prescribed medications.
Limitations and Research Gaps
Several limitations must be acknowledged when considering PPG for drug response monitoring:
Inter-individual variability. The same drug dose produces different PPG responses across individuals due to differences in baseline vascular tone, autonomic function, body composition, and genetic polymorphisms affecting drug metabolism. Population-level correlations between drug dose and PPG response are moderate (r = 0.5-0.8), but individual-level prediction requires personalized baseline calibration.
Confounding factors. Temperature, hydration, posture, emotional state, and concurrent medications all affect PPG parameters independently of the drug being monitored. In the ICU setting, where patients may be receiving 5-10 concurrent medications, isolating the PPG effect of a single agent is particularly challenging. Robust signal processing and motion artifact removal are essential prerequisites.
Regulatory and clinical workflow integration. PPG-derived pharmacodynamic parameters are not yet integrated into standard clinical decision support systems for most drug classes. The SPI and PVI represent exceptions in the anesthesia domain, but broader adoption requires prospective outcome studies demonstrating clinical benefit.
Conclusion
PPG provides a rich, continuously available window into the cardiovascular effects of pharmacological agents. The technology is already embedded in clinical practice through pulse oximetry, and advanced PPG analysis extends its utility to drug response monitoring, anesthesia assessment, and fluid management. The evidence base is strongest for vasodilator response tracking (AIx, SDPPG ratios), fluid responsiveness prediction (PVI), nociception assessment (SPI), and regional anesthesia confirmation (PI).
For researchers and engineers developing PPG-based drug monitoring applications, the key challenge is moving from group-level pharmacodynamic correlations to individual-level prediction models that account for inter-individual variability and confounding factors. Integration with population PK-PD models and closed-loop drug delivery systems represents the most impactful translational pathway. For more on PPG signal analysis methods, explore our algorithms documentation and our guide to PPG-detectable health conditions.